M.K. Rohith Krishnan

1 ta ish

Fargʻona politexnika instituti

1. Comment on “Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study”

   Shobana Chandrasekar, M.K. Rohith Krishnan, Umesh Kumar

   MaqolaOAOchiq kirishMultiple Myeloma Research and TreatmentsJournal of the Formosan Medical Association20260 iqtibos

   ABIABI:AkademIndex/2026.article.021129